Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 3.73
ALNY's Cash-to-Debt is ranked lower than
64% of the 983 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. ALNY: 3.73 )
Ranked among companies with meaningful Cash-to-Debt only.
ALNY' s Cash-to-Debt Range Over the Past 10 Years
Min: 3.29  Med: No Debt Max: No Debt
Current: 3.73
Equity-to-Asset 0.73
ALNY's Equity-to-Asset is ranked higher than
57% of the 732 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ALNY: 0.73 )
Ranked among companies with meaningful Equity-to-Asset only.
ALNY' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.99  Med: 0.64 Max: 0.92
Current: 0.73
-0.99
0.92
Interest Coverage N/A
ALNY's Interest Coverage is ranked lower than
55% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALNY: N/A )
Ranked among companies with meaningful Interest Coverage only.
ALNY' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: N/A
N/A
No Debt
Piotroski F-Score: 2
Altman Z-Score: 10.18
Beneish M-Score: -2.17
WACC vs ROIC
22.72%
-111.75%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -716.42
ALNY's Operating Margin % is ranked lower than
73% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. ALNY: -716.42 )
Ranked among companies with meaningful Operating Margin % only.
ALNY' s Operating Margin % Range Over the Past 10 Years
Min: -900.33  Med: -188.54 Max: -28.95
Current: -716.42
-900.33
-28.95
Net Margin % -705.11
ALNY's Net Margin % is ranked lower than
74% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -84.10 vs. ALNY: -705.11 )
Ranked among companies with meaningful Net Margin % only.
ALNY' s Net Margin % Range Over the Past 10 Years
Min: -869.63  Med: -163.4 Max: -27.3
Current: -705.11
-869.63
-27.3
ROE % -41.00
ALNY's ROE % is ranked lower than
52% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. ALNY: -41.00 )
Ranked among companies with meaningful ROE % only.
ALNY' s ROE % Range Over the Past 10 Years
Min: -84.12  Med: -39.64 Max: -13.08
Current: -41
-84.12
-13.08
ROA % -32.33
ALNY's ROA % is ranked lower than
52% of the 992 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. ALNY: -32.33 )
Ranked among companies with meaningful ROA % only.
ALNY' s ROA % Range Over the Past 10 Years
Min: -48.05  Med: -23.41 Max: -5.01
Current: -32.33
-48.05
-5.01
ROC (Joel Greenblatt) % -512.30
ALNY's ROC (Joel Greenblatt) % is ranked lower than
53% of the 952 Companies
in the Global Biotechnology industry.

( Industry Median: -369.38 vs. ALNY: -512.30 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ALNY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2120.98  Med: -554.62 Max: -149.42
Current: -512.3
-2120.98
-149.42
3-Year Revenue Growth Rate -10.40
ALNY's 3-Year Revenue Growth Rate is ranked lower than
68% of the 528 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. ALNY: -10.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ALNY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -8.15 Max: 108
Current: -10.4
0
108
3-Year EBITDA Growth Rate 52.70
ALNY's 3-Year EBITDA Growth Rate is ranked higher than
89% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: 0.20 vs. ALNY: 52.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ALNY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -64.8  Med: 3.5 Max: 65.3
Current: 52.7
-64.8
65.3
3-Year EPS without NRI Growth Rate 48.90
ALNY's 3-Year EPS without NRI Growth Rate is ranked higher than
90% of the 553 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. ALNY: 48.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ALNY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -66.7  Med: 6.6 Max: 52.8
Current: 48.9
-66.7
52.8
GuruFocus has detected 3 Warning Signs with Alnylam Pharmaceuticals Inc $ALNY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ALNY's 30-Y Financials

Financials (Next Earnings Date: 2017-08-05 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:BIVV, NAS:IONS, NAS:UTHR, NAS:EXEL, NAS:TSRO, NAS:KITE, NAS:ARIA, NAS:BLUE, NAS:ALKS, NAS:TECH, NAS:JAZZ, NAS:GLPG, NAS:SGEN, NAS:NBIX, OTCPK:PPTDF, NAS:ACAD, OTCPK:BTGGF, NAS:CBPO, NAS:SAGE, NAS:ICPT » details
Traded in other countries:DUL.Germany,
Headquarter Location:USA
Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.

Alnylam Pharmaceuticals is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. Alnylam has partnered several pipeline candidates--including amyloidosis drug patisiran, hemophilia drug fitusiran, and cholesterol drug inclisiran. Upfront fees from research partnerships with firms such as Sanofi, Novartis, Medtronic, and Roche have boosted Alnylam's cash levels, and the firm stands to see milestones and royalties from drugs commercialized under these agreements.

Top Ranked Articles about Alnylam Pharmaceuticals Inc

High Return Covered Call Trades for Alnylam Pharmaceuticals, Lumber Liquidators, Nutrisystem, 500.Com, and Wix.com!
Weekly Top Insider Buys Highlight for Week of Oct. 14 Top insider buys of the week, including Monsanto, Alnylam Pharmaceuticals, Synergy Resources and Ferrellgas Partners
Largest Insider buys for Monsanto (NYSE:MON), Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Synergy Resources Corp. (SYRG) and Ferrellgas Partners LP (NYSE:FGP). Read more...
Low Valuation Ratios Lead to Strong Portfolio Returns Backtesting Ben Graham’s Lost Formula strategy
Known as the “Father of Value Investing,” Benjamin Graham intelligently invested money in the stock market. Read more...

Ratios

vs
industry
vs
history
PB Ratio 8.81
ALNY's PB Ratio is ranked lower than
78% of the 888 Companies
in the Global Biotechnology industry.

( Industry Median: 3.78 vs. ALNY: 8.81 )
Ranked among companies with meaningful PB Ratio only.
ALNY' s PB Ratio Range Over the Past 10 Years
Min: 2.07  Med: 4.82 Max: 21.37
Current: 8.81
2.07
21.37
PS Ratio 124.68
ALNY's PS Ratio is ranked lower than
87% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 11.91 vs. ALNY: 124.68 )
Ranked among companies with meaningful PS Ratio only.
ALNY' s PS Ratio Range Over the Past 10 Years
Min: 3.1  Med: 21.3 Max: 222.78
Current: 124.68
3.1
222.78
Current Ratio 6.23
ALNY's Current Ratio is ranked higher than
64% of the 977 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. ALNY: 6.23 )
Ranked among companies with meaningful Current Ratio only.
ALNY' s Current Ratio Range Over the Past 10 Years
Min: 1.88  Med: 4.97 Max: 18.24
Current: 6.23
1.88
18.24
Quick Ratio 6.23
ALNY's Quick Ratio is ranked higher than
65% of the 976 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. ALNY: 6.23 )
Ranked among companies with meaningful Quick Ratio only.
ALNY' s Quick Ratio Range Over the Past 10 Years
Min: 1.88  Med: 4.97 Max: 18.24
Current: 6.23
1.88
18.24
Days Sales Outstanding 120.83
ALNY's Days Sales Outstanding is ranked lower than
78% of the 627 Companies
in the Global Biotechnology industry.

( Industry Median: 64.26 vs. ALNY: 120.83 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALNY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.57  Med: 34.48 Max: 288.31
Current: 120.83
0.57
288.31

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.50
ALNY's 3-Year Average Share Buyback Ratio is ranked higher than
54% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: -11.90 vs. ALNY: -10.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALNY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -331.8  Med: -15.2 Max: -1
Current: -10.5
-331.8
-1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 28.62
ALNY's Price-to-Net-Cash is ranked lower than
85% of the 532 Companies
in the Global Biotechnology industry.

( Industry Median: 7.50 vs. ALNY: 28.62 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ALNY' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.7  Med: 9.38 Max: 92.77
Current: 28.62
3.7
92.77
Price-to-Net-Current-Asset-Value 24.94
ALNY's Price-to-Net-Current-Asset-Value is ranked lower than
85% of the 667 Companies
in the Global Biotechnology industry.

( Industry Median: 7.00 vs. ALNY: 24.94 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ALNY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.54  Med: 9.15 Max: 82.06
Current: 24.94
3.54
82.06
Price-to-Tangible-Book 8.83
ALNY's Price-to-Tangible-Book is ranked lower than
70% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. ALNY: 8.83 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ALNY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.2  Med: 4.9 Max: 15.16
Current: 8.83
2.2
15.16
Price-to-Median-PS-Value 5.85
ALNY's Price-to-Median-PS-Value is ranked lower than
95% of the 667 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. ALNY: 5.85 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ALNY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.16  Med: 1.11 Max: 8.97
Current: 5.85
0.16
8.97
Earnings Yield (Greenblatt) % -6.10
ALNY's Earnings Yield (Greenblatt) % is ranked higher than
52% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -7.87 vs. ALNY: -6.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALNY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -79.8  Med: -9.4 Max: -1.6
Current: -6.1
-79.8
-1.6

More Statistics

Revenue (TTM) (Mil) $58.77
EPS (TTM) $ -4.82
Beta3.47
Short Percentage of Float22.66%
52-Week Range $31.38 - 84.69
Shares Outstanding (Mil)86.19

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 76 145 214
EPS ($) -5.43 -5.66 -4.13
EPS without NRI ($) -5.43 -5.66 -4.13
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ALNY

Headlines

Articles On GuruFocus.com
Capital One Financial Corporation to Webcast Conference Call on Second Quarter 2017 Earnings Jun 22 2017 
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors With Over $200k in Losses o Jun 22 2017 
Gartner Names CSRA to Global Top 100 in IT Jun 22 2017 
Twitter and Sela Sport Partner to Live Stream 2017 Arab Championship Matches Jun 22 2017 
ManpowerGroup Appoints Becky Frankiewicz as President ManpowerGroup North America Jun 22 2017 
Southwest Airlines Adds New Nonstop Route Linking San Diego And Tampa Jun 22 2017 
Shentel Awarded Independent Operator of the Year by Cablefax Jun 22 2017 
The Weather Channel Launches Advanced Global Radar App Jun 22 2017 
root9B Releases Technical Analysis on Active Malware Campaign After Briefing Law Enforcement Jun 22 2017 
MainStay Suites in Sidney, Montana, Wins Hotel of the Year Award Jun 22 2017 

More From Other Websites
Alnylam CEO, John Maraganore, Named BIO Chair for 2017-2018 Term Jun 19 2017
Why is Alnylam's (ALNY) Stock Close to 100% this Year? Jun 15 2017
Alnylam Significantly Expands Patent Portfolio with New Allowances from United States Patent and... Jun 12 2017
Why Is Alnylam (ALNY) Up 31.2% Since the Last Earnings Report? Jun 08 2017
Alnylam Expands Third Annual “Helping Hands” Community Service Day Globally to Benefit 18... Jun 07 2017
Top Losers in the Healthcare Sector: May 22–26, 2017 May 31 2017
Alnylam Pharma stock rises 1.5% after FDA gives drug 'breakthrough therapy' designation May 31 2017
FDA Grants Breakthrough Therapy Designation for Alnylam’s Givosiran for the Prophylaxis of Attacks... May 31 2017
Biotech Musical Chairs: Who Leads Next May 31 2017
Alnylam to Webcast Presentation at Jefferies 2017 Healthcare Conference May 30 2017
Regeneron Presents Positive Phase II Data on HoFH Candidate May 25 2017
Alnylam Pharmaceuticals (ALNY) Progressing Well on Pipeline May 25 2017
Biotech Movers: Inovio, Neurocrine, Alnylam May 24 2017
Alnylam Pharmaceuticals Prices Public Offering of Common Stock May 24 2017
Alnylam Pharmaceuticals Announces Proposed Public Offering of Common Stock May 23 2017
Alnylam Pharmaceuticals (ALNY) Looks Good: Stock Jumps 16.3% May 16 2017
How Ionis Helped Rival Alnylam — But Tanked Itself — On A Key Trial May 15 2017
Safety Concerns Ding Ionis May 15 2017
Why Ionis Pharmaceuticals Inc Tanked and Alnylam Pharmaceuticals, Inc. Is Soaring Today May 15 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}